Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshimi Takano

Showing results (1-10 of 178) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerToshimi Takano
Breast Cancer (Tokyo, Japan)|April 29, 2020
The era of meta-analyses-based recommendations: how were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established?Toshimi Takano
The New England Journal of Medicine|October 22, 2005
Erlotinib in lung cancerToshimi Takano, Yuichiro Ohe
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 16, 2021
[Ⅳ. Development of Antibody-Drug Conjugate in Triple Negative Breast Cancer]Yukinori Ozaki, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 10, 2023
[Challenges to International Collaborative Clinical Research and Approval Disparities]Yukinori Ozaki, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 22, 2024
[Ⅲ. Clinical Trials of Trastuzumab Deruxtecan for HER2-Low Advanced Breast Cancer]Rika Kizawa, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2003
[Doctor-initiated clinical trials and the revised pharmaceutical affairs law]Toshimi Takano, Nagahiro Saijo
The New England Journal of Medicine|February 17, 2012
Adjuvant trastuzumab in HER2-positive breast cancerDaisuke Kaji, Yuji Miura, Toshimi Takano
The New England Journal of Medicine|December 15, 2010
Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancerYoichi Naito, Yuji Miura, Toshimi Takano
The New England Journal of Medicine|June 13, 2019
Sacituzumab Govitecan-hziy in Triple-Negative Breast CancerYukinori Ozaki, Jun Masuda, Toshimi Takano
Pageof 18

Showing results (1-10 of 178) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|January 6, 2010
Treatment of lung cancerToshimi Takano
Breast Cancer (Tokyo, Japan)|April 29, 2020
The era of meta-analyses-based recommendations: how were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established?Toshimi Takano
The New England Journal of Medicine|October 22, 2005
Erlotinib in lung cancerToshimi Takano, Yuichiro Ohe
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 16, 2021
[Ⅳ. Development of Antibody-Drug Conjugate in Triple Negative Breast Cancer]Yukinori Ozaki, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 10, 2023
[Challenges to International Collaborative Clinical Research and Approval Disparities]Yukinori Ozaki, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 22, 2024
[Ⅲ. Clinical Trials of Trastuzumab Deruxtecan for HER2-Low Advanced Breast Cancer]Rika Kizawa, Toshimi Takano
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2003
[Doctor-initiated clinical trials and the revised pharmaceutical affairs law]Toshimi Takano, Nagahiro Saijo
The New England Journal of Medicine|February 17, 2012
Adjuvant trastuzumab in HER2-positive breast cancerDaisuke Kaji, Yuji Miura, Toshimi Takano
The New England Journal of Medicine|December 15, 2010
Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancerYoichi Naito, Yuji Miura, Toshimi Takano
The New England Journal of Medicine|June 13, 2019
Sacituzumab Govitecan-hziy in Triple-Negative Breast CancerYukinori Ozaki, Jun Masuda, Toshimi Takano
Pageof 18